Red Wine Chemical Enhances Mesothelioma Chemotherapy

A new experimental treatment combining a chemical found in red wine and a popular chemotherapy drug showed a powerful synergistic effect in targeting pleural mesothelioma cells. Researchers at Soon Chun Hyang University Hospital Cheonan in South Korea combined the platinum-based chemotherapy drug cisplatin with resveratrol, a natural antioxidant found in wine and red grapes. The result successfully induced apoptosis, or the process of natural cell death, in malignant mesothelioma cells. Cisplatin has long been one of the most popular drugs to treat mesothelioma and a variety of other cancers. But like many chemotherapy drugs, cisplatin’s efficacy remains limited. Resistance can develop following prolonged cycles or can be present innately in patients. The resveratrol made mesothelioma cells much more vulnerable to cisplatin, an effect Soon Chun Hyang researchers hope will translate into future treatment options. Furthermore, the data showed the increased resistance of the cells is related to the activation of self-defensive autophagy, or the destructive mechanism of the cell that disassembles unnecessary or dysfunctional components. “The molecular basis of the synergistic anti-cancer activities of [cisplatin] and [resveratrol] is not yet understood in detail,” lead investigator Yoon-Jin Lee wrote in the study. “However, emerging studies have revealed that [resveratrol] acts as an excellent candidate for potentiation of platinum treatment in vitro ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: chemotherapy for mesothelioma cisplatin for mesothelioma mesothelioma treatment with red wine red wine for cancer resveratrol and cisplatin for cancer resveratrol in red wine Soon Chun Hyang University Hospital Cheonan Source Type: news

Related Links:

Ataxia-telangiectasia (A-T), an autosomal recessive disorder characterized by progressive neurologic dysfunction, oculocutaneous telangiectasia, immunodeficiency, and cancer susceptibility, is caused by mutations in the ATM gene. A previous study of 4 A-T patients identified 2 rare homozygous missense mutations residing on the same allele of the ATM gene: c.1514T>C and c.1547T>C, which were shown to decrease ATM levels and increase T-cell acute lymphoblastic leukemia predisposition. We studied 5 patients from 2 consanguineous Bedouin families of the same tribe, presenting with A-T. Whole-exome sequencing data identif...
Source: Journal of Pediatric Hematology Oncology - Category: Hematology Tags: Online Articles: Original Articles Source Type: research
The University of Pennsylvania's Abramson Cancer Center had received a $10.7 million grant from the National Cancer Institute to study CAR-T cells in solid tumors The five-year grant from the NCI's will support new experimental approaches in lung cancer and mesothelioma being conducted by Penn researchers at its translational center of excellence for lung cancer immunology “Although CAR-T cells have been revolutionized the treatment of leukemia and bone marrow cancers, we have not yet had the…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news
Thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering (MSK) Cancer Center believes customized gene therapy will soon change the way pleural mesothelioma is treated. Adusumilli, director of the Mesothelioma Program at MSK, has worked for a decade on developing tumor immunology for thoracic malignancies. He is currently the principal investigator of a phase I clinical trial involving specially prepared immune cells — chimeric antigen receptor (CAR) T cells — that have shown impressive efficacy with mesothelioma. “I think this is going to change the paradigm of treating mesotheliom...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
This study reveals important areas of progress in cancer outcomes in Canada since the early 1990s. It also sheds light on cancers for which there has seemingly been no improvement in five-year net survival over a 20-year period. PMID: 30230521 [PubMed - in process]
Source: Health Reports - Category: International Medicine & Public Health Tags: Health Rep Source Type: research
John Feal believes more people will die from illnesses related to 9/11 than from the terrorist attack at the World Trade Center. He should know. He’s a first responder who witnesses it every day. And he is not alone in his belief. Feal, a longtime advocate for Sept. 11 survivors and those dying from diseases related to the terrorist attacks, will again host the annual naming ceremony at the 9/11 Responders Remembered Park in Smithtown, Long Island. Each year he reads the names of those who have died within the past year. And each year, the list is longer than the last. On the 17th anniversary of the terrorist attack...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   B-cell Acute Lymphoblastic Leukemia;   Lymphoma;   Myeloid Leukemia;   Multiple Myeloma;   Hepatoma;   Gastric Cancer;   Pancreatic Cancer;   Mesothelioma;   Colorectal Cancer;   Esophagus Cancer;   Lung Cancer;   Glioma;   Melanoma;   Synovial Sarcoma;   Ovarian Cancer ;   Renal Carcinoma Intervention:   Biological: CAR-T cell immunotherapy Sponsors:   Shenzhen BinDeBio Ltd.;   The First Affiliated Hospital of Zhengzhou University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
This study strengthens the suspicion that, next to germline BAP1 alterations, other genetic factors might predispose families to the development of MM,” the authors wrote. Mutations in only one gene called BAP1 have been shown to increase risk of mesothelioma. However, experts suspect other genes may play a role in the disease. This new study supports the idea that other genes can predispose a person — or even an entire family — to mesothelioma. Hints of Genetic Influence on Mesothelioma Risk Asbestos exposure is the No. 1 cause of mesothelioma. However, some families seem to have more cases of mesothe...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
In conclusion, inhibition of ODC1 by DFMO was crucial in facilitating BCT‑100 treatment in lung adenocarcinoma that was partially mediated by depleting arginine and polyamines with consequent apoptosis. PMID: 30066894 [PubMed - as supplied by publisher]
Source: Oncology Reports - Category: Cancer & Oncology Tags: Oncol Rep Source Type: research
Conclusions: Most cancer outcomes are consistent with background risk in refinery workers. This work has clarified an excess mesothelioma risk, conditional on study quality stratification. Continued surveillance is warranted for melanoma and ALL.
Source: Journal of Occupational and Environmental Medicine - Category: Occupational Health Tags: Original Articles Source Type: research
Standard mesothelioma treatment options include surgery, radiation therapy, chemotherapy and multimodal therapy. These standard therapies do not offer a cure for people with mesothelioma, and that’s why scientists continue searching for better ways to treat the disease. Researchers at the Scripps Research Institute in Jupiter, Florida, have created a precision medicine approach that targets a protein on the surface of cancer cells to kill tumors. Although the drug was not specifically designed for mesothelioma patients, it may offer a more effective way to manage the disease in the future. The treatment is a type of...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Chemistry | Chemotherapy | Clinical Trials | Environmental Health | Grapes | Hospitals | Leukemia | Mesothelioma | Molecular Biology | Study | Toxicology